GlassScriptPhysician profile
Rohit Masih
NPI 1306206669
$5,369.55
in general payments reported to CMS, 2019-2025
16 companies · $2,691 in 2025
The $2,691 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.74 · 2020: $22.03 · 2022: $409 · 2023: $672 · 2024: $1,488 · 2025: $2,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Travel and Lodging: $1,867 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.37 |
| Travel and Lodging | $1,866.77 |
| Education | $474.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $3,101.95 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $1,001.15 | 2024-2025 | Ensite, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $367.93 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $261.74 | 2019-2023 | Xarelto |
| Pfizer INC. | $136.45 | 2022-2023 | |
| Amgen INC. | $111.43 | 2023 | Repatha |
| Allergan, INC. | $87.18 | 2019-2020 | |
| Edwards Lifesciences Corporation | $81.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.61 | 2023 | Xifaxan |
| Boston Scientific Corporation | $33.04 | 2023 | |
| Abiomed | $32.95 | 2024 | Impella |
| Irhythm Technologies, INC. | $27.11 | 2024 | Zio Monitor, Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.55 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.77 | 2023 | Ultomiris |
| Bridgebio Pharma, INC. | $16.41 | 2025 | Attruby |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.03 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Masih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.